USA - NASDAQ:YS - KYG9845F1090 - Common Stock
Overall YS gets a fundamental rating of 2 out of 10. We evaluated YS against 538 industry peers in the Biotechnology industry. Both the profitability and financial health of YS have multiple concerns. YS is valued expensive and it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -17.59% | ||
ROE | -50.88% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 77.68% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | N/A | ||
Altman-Z | -0.65 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.41 | ||
Quick Ratio | 1.09 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.02
+0.11 (+12.45%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2.02 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.5 | ||
P/tB | 2.88 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -17.59% | ||
ROE | -50.88% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 77.68% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.41 | ||
Quick Ratio | 1.09 | ||
Altman-Z | -0.65 |